Yes, someone called this $649-over-MSRP RTX 5090 a ‘deal' — here are the Prime Day GPUs that aren't a scam
Case in point: people are hyping up a '$1,000 off' RTX 5090 deal… which still costs $2,649. That's almost $700 above MSRP. I genuinely hope you weren't mid-sip, because yeah — it's that bad.
Let's get something straight: a price drop down to MSRP is not a deal. Neither is shaving a few bucks off a price that's already been scalped into another dimension.
That said, not all hope is lost. I've dug through the chaos to find the best Prime Day GPU deals that actually make sense — including some MSRP-level pricing on the latest cards, and actual discounts if you're shopping in the U.K.
So, come with me. Let's skip the overpriced nonsense and track down the graphics cards actually worth buying on Prime Day.
If you've got the money for it, the RTX 5090 is the best GPU you can buy right now — no workload is safe from this tearing through it at max speed and the gaming performance is simply unmatched.
Been saving and have the flexibility to go $649 over MSRP? Don't let me stop you!
Get instant access to breaking news, the hottest reviews, great deals and helpful tips.
The PNY RTX 5090 overclockable GPU is a true triple-fan monster that is capable of 4K gaming with every setting turned up to max without breaking a sweat. You can snag $1,000 off it right now, but that price is still very high.
But enough showing off about the U.K. — let's try and find my friends in the States a little something. Here are 3 tips for your GPU-buying mission:
Got all that? Good! Rather than go immediately for the first thing you see a big red sale sticker on (that's not actually a sale), go for these instead.
At $30 over MSRP, this is a stellar budget pick for your gaming PC. I've been testing the Intel Arc B580 recently (review to come), and you can get some impressive frame rates at 1080p and 1440p out of this, alongside that 12GB of video memory for plenty of headroom.
This falls into that $50 area of acceptable price increases, and you're getting a rather impressive GPU here with 16GB of video memory and all of AMD's upcoming FSR 4 tech that is really taking the fight to Nvidia's DLSS.
Well, well well! A 16GB version of the 5060 Ti at MSRP. This is going to get snapped up quick, so be speedy about grabbing this — definitely an encouraging sign of normalizing prices.
My main gripe with the RTX 5070 was the fact it was never available at retail price. Well, Best Buy has shocked me with this MSRP beast of a buy. Snag it while you can.
I know, I know. At $80 over MSRP, we're creeping into overpriced territory here. But for what I've been able to crack out of the RTX 5070 Ti, this is the lowest price I can find on my favorite GPU.
The PNY RTX 5090 overclockable GPU is a true triple-fan monster that is capable of 4K gaming with every setting turned up to max without breaking a sweat. You can snag $1,000 off it right now, but that price is still very high.
This is a sizable discount on a Skytech Rampage gaming PC packing a speedy liquid-cooled Intel Core i7 14700F CPU, a powerful Nvidia GeForce RTX 5070 Ti GPU, 32GB of DDR5 RAM and 1TB of SSD storage.
I've checked for GPU stock over the course of this entire year, and one thing has become abundantly clear — scalping is not really a thing in Britain.
That's not to say it doesn't exist. There are still plenty of cards that are being sold for £30-50 more. But stocking issues don't seem to be plaguing the U.K. as much, and because of that, retailers are selling some models at (or even below) recommended retail price (RRP).
This is for the model with 16GB of video memory (the right one to buy), and scalpers be damned you can get it for £2 below RRP!
That's over £30 below RRP for the RTX 5070. Given my main gripe with this was the price to performance, this certainly makes it a much more tempting card to get.
So the RTX 5070 Ti (my personal favorite of the bunch) just dropped an extra £50 below retail price!
Now this is a surprise! Even the RTX 5080 is £30 below RRP too.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Nvidia CEO downplays role in lifting US ban on chip sales to China
BEIJING (AP) — The head of Nvidia downplayed his role in getting the U.S. government to lift a ban on selling an advanced computer chip in China and said it will take time to ramp up production once orders for the AI-processor come in. CEO Jensen Huang, speaking Wednesday in the Chinese capital Beijing, was upbeat about the prospects for the H20 chip, which was designed to meet U.S. restrictions on technology exports to China but nonetheless blocked in April. He met U.S. President Donald Trump before his trip and his company announced this week it had received assurances that sales to China would be approved. 'I don't think I changed his mind,' Huang told a cluster of journalists, many of whom asked for his autograph or to take selfies with him. A carefully organized press conference at a luxury hotel descended into a crowd scene when Huang arrived in his trademark leather jacket and started taking questions randomly in his characteristic casual style. Export controls and tariffs were something companies must adapt to in a world he said was reconfiguring itself. He described his role as informing governments in the U.S. and elsewhere of the nature and unintended consequences of their policies. The decision to lift the ban on the H20 chip was entirely in the hands of the American and Chinese governments and whatever trade talks they had, he said. 'We can only influence them, inform them, do our best to provide them with facts,' Huang said. 'And then beyond that is out of our control.' Nvidia said in April that sales restrictions on its chip in China on national security grounds would cost the company $5.5 billion. The White House also blocked a chip from Advanced Micro Devices. Both companies say the Commerce Department is now moving forward with license applications to export them to China. Huang said his company would likely be able to recover some of its losses but it's unclear how much. That will depend on how many H20 orders are received and how quickly Nvidia can meet the demand. 'I think that H20 is going to be very successful here,' he said, noting the chip's memory bandwidth makes it a good fit for the AI models being developed by Chinese companies such as DeepSeek and Alibaba. Huang also touted the release of a new RTX Pro graphics chip that he said would power the development of humanoid robots. He described robotic systems with teams of robots working alongside people as the next wave in AI. 'Because there's so much robotics innovation going on and so much smart factory work being done here and the supply chain is so vast, RTX Pro is perfect,' he said. Ken Moritsugu, The Associated Press
Yahoo
20 minutes ago
- Yahoo
Here's What to Expect From Zebra Technologies' Next Earnings Report
Valued at a market cap of $16.4 billion, Zebra Technologies Corporation (ZBRA) provides enterprise asset intelligence solutions in the automatic identification and data capture solutions industry. The Lincolnshire, Illinois-based company's portfolio includes barcode scanners, mobile computers, RFID readers, specialty printers, and software solutions used across sectors such as retail, healthcare, logistics, manufacturing, and government. It is expected to announce its fiscal Q2 earnings for 2025 before the market opens on Tuesday, Aug. 5. Ahead of this event, analysts expect this tech company to report a profit of $2.80 per share, up 5.7% from $2.65 per share in the year-ago quarter. The company has topped Wall Street's earnings estimates in three of the last four quarters, while missing on another occasion. In Q1, ZBRA's EPS of $4.02 outpaced the forecasted figure by 11.7%. Dear Nvidia Stock Fans, Mark Your Calendars for July 16 How to Buy Tesla for a 13% Discount, or Achieve a 26% Annual Return Retirement Ready: 3 Dividend Stocks to Set and Forget Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. For fiscal 2025, analysts expect ZBRA to report a profit of $12.12 per share, up 2.4% from $11.84 per share in fiscal 2024. Furthermore, its EPS is expected to grow 18.5% year-over-year to $14.36 in fiscal 2026. Shares of ZBRA have declined 2.4% over the past 52 weeks, lagging behind both the S&P 500 Index's ($SPX) 10.9% uptick and the Technology Select Sector SPDR Fund's (XLK) 10.1% return over the same time frame. On Apr. 29, shares of ZBRA surged 5.2% after its better-than-expected Q1 earnings release. The company's revenue improved 11.3% year-over-year to $1.3 billion, surpassing the consensus estimates by 2.3%. Moreover, due to a solid growth in both its adjusted gross and operating profit margins, its adjusted EPS of $4.02 advanced 41.5% from the year-ago quarter and topped analyst expectations by a notable margin of 11.7%. Wall Street analysts are moderately optimistic about ZBRA's stock, with a "Moderate Buy" rating overall. Among 16 analysts covering the stock, nine recommend "Strong Buy," one indicates a "Moderate Buy," and six suggest "Hold.' The mean price target for ZBRA is $347.64, indicating an 8.8% potential upside from the current levels. On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
20 minutes ago
- Yahoo
What to Expect From Baxter International's Q2 2025 Earnings Report
Baxter International Inc. (BAX), headquartered in Deerfield, Illinois, develops and provides a portfolio of healthcare products. With a market cap of $14.6 billion, the company develops, manufactures, and markets products and technologies related to hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company's products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and research laboratories. The global Medtech leader is expected to announce its fiscal second-quarter earnings for 2025 on Tuesday, Aug. 5. Ahead of the event, analysts expect BAX to report a profit of $0.60 per share on a diluted basis, down 11.8% from $0.68 per share in the year-ago quarter. The company has consistently surpassed Wall Street's EPS estimates in its last four quarterly reports. Dear Nvidia Stock Fans, Mark Your Calendars for July 16 How to Buy Tesla for a 13% Discount, or Achieve a 26% Annual Return Retirement Ready: 3 Dividend Stocks to Set and Forget Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. For the full year, analysts expect BAX to report EPS of $2.50, up 32.3% from $1.89 in fiscal 2024. Similarly, its EPS is expected to rise 7.6% year-over-year to $2.69 in fiscal 2026. BAX stock has underperformed the S&P 500 Index's ($SPX) 10.9% gains over the past 52 weeks, with shares down 16.8% during this period. Similarly, it underperformed the Health Care Select Sector SPDR Fund's (XLV) 10.3% dip over the same time frame. BAX's decline in performance is a direct result of the considerable expenses resulting from the damage caused by Hurricane Helene to its North Cove facility, which is a critical supplier of IV fluids in the U.S. This indicates weaknesses in the company's operational management and underscores the need for improvements to mitigate such risks in the future. On May 1, BAX shares closed down more than 1% after the company reported its Q1 results. Its revenue stood at $2.6 billion, up 5.4% year-over-year. The company's adjusted EPS declined 4.6% year-over-year to $0.62. Analysts' consensus opinion on BAX stock is reasonably bullish, with an overall 'Moderate Buy' rating. Out of 15 analysts covering the stock, five advise a 'Strong Buy' rating, nine give a 'Hold,' and one recommends a 'Moderate Sell.' BAX's average analyst price target is $36.28, indicating a potential upside of 28.4% from the current levels. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
